Today: 20 March 2026
Subscribe
Browse Category

Pharmaceuticals 5 February 2026 - 6 February 2026

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly stock rebounds after FDA flags copycat weight-loss drugs; what’s next for LLY

Eli Lilly shares rose 3% Friday after the FDA chief warned of a crackdown on non-approved copycat weight-loss drugs. The rebound followed an 8% drop Thursday, triggered by news of a $49 compounded rival to Novo Nordisk’s Wegovy. Investors are watching Lilly’s 2026 outlook and the FDA’s April decision on its oral obesity drug. Fourth-quarter revenue jumped 43% to $19.3 billion, led by strong sales of Mounjaro and Zepbound.
6 February 2026
····
Pfizer stock slips before open as TrumpRx discounts debut and FDA priority review adds a catalyst

Pfizer stock slips before open as TrumpRx discounts debut and FDA priority review adds a catalyst

Pfizer shares fell 1.1% to $26.49 in premarket trading after the TrumpRx discount drug portal launched Thursday, raising concerns over U.S. drug pricing. Pfizer said its TrumpRx program offers discounts of up to 85% on more than 30 medicines. The FDA granted Priority Review for expanding Hympavzi use in younger hemophilia patients, with a decision expected in the second quarter.
6 February 2026
··
Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers (HIMS) stock slides premarket as FDA targets “copycat drugs” over $49 Wegovy pill

Hims & Hers Health shares fell 3.8% to $23.48 in premarket trading Friday after FDA Commissioner Marty Makary warned of a crackdown on “illegal copycat drugs.” The drop followed Hims’ launch of a $49 compounded version of Novo Nordisk’s Wegovy pill. Novo Nordisk said it would pursue legal and regulatory action, calling Hims’ move “illegal mass compounding.” Investors are watching for FDA enforcement and lawsuits ahead of Hims’ Feb. 23 report.
6 February 2026
····
Novo Nordisk stock rebounds as FDA warns on illegal Wegovy copycats

Novo Nordisk stock rebounds as FDA warns on illegal Wegovy copycats

Novo Nordisk shares rose nearly 5% Friday after the FDA said it would target mass-marketed, unapproved drug copies. The move follows Hims & Hers launching a $49 compounded version of Novo’s Wegovy pill, prompting Novo to threaten legal action. The stock remains near its 52-week low after a sharp drop earlier this week. Investors await FDA enforcement and Novo’s next legal steps.
6 February 2026
··
AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss

AbbVie stock ticks higher after hours as traders digest 2026 outlook after Rinvoq miss

AbbVie shares rose 0.7% to $219.02 in after-hours trading Thursday, rebounding after a nearly 6% drop following its earnings report. Skyrizi beat sales estimates with $5.01 billion, while Rinvoq missed at $2.37 billion. The company raised its 2026 forecast for the pair to $31.6 billion. Investors remain focused on whether new drugs can offset Humira’s ongoing decline.
6 February 2026
···
Eli Lilly stock price sinks after $49 weight-loss pill jolt hits LLY

Eli Lilly stock price sinks after $49 weight-loss pill jolt hits LLY

Eli Lilly shares fell 7.8% to $1,020.84 in after-hours trading Thursday after Reuters reported Hims & Hers began selling a $49 compounded version of Novo Nordisk’s Wegovy, raising discount fears in the GLP-1 drug market. Earlier, Lilly posted a 43% jump in quarterly revenue to $19.29 billion, led by Mounjaro and Zepbound, and forecast 2026 sales above Wall Street estimates.
5 February 2026
··
Merck stock rises 2% in New York as MRK traders size up outlook and a fresh RSV approval

Merck stock rises 2% in New York as MRK traders size up outlook and a fresh RSV approval

Merck shares rose about 2% to $120.72 Thursday after forecasting 2026 sales and profits below Wall Street estimates, citing patent expiries on older drugs. The company reported Q4 global sales of $16.4 billion and non-GAAP EPS of $2.04, and expects 2026 sales of $65.5–$67.0 billion. Health Canada approved ENFLONSIA for RSV prevention in infants. FDA review of WINREVAIR is set for September 21, 2026.
5 February 2026
··
JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

Johnson & Johnson shares rose 1.3% to $237.59 after the company asked the U.S. Supreme Court to review a shareholder lawsuit over talc safety claims. The petition challenges a Third Circuit ruling on class certification standards. The case is separate from ongoing talc injury suits. Investors are also watching for new data on J&J’s atrial fibrillation devices at a cardiology event this week.
5 February 2026
··
Bristol Myers Squibb stock rises on 2026 guidance as Eliquis price cut comes into view

Bristol Myers Squibb stock rises on 2026 guidance as Eliquis price cut comes into view

Bristol Myers Squibb shares rose 1.7% to $58.58 by midday Thursday, bucking a broader market decline, after the company issued a 2026 outlook projecting up to $47.5 billion in revenue. Quarterly revenue increased 1% to $12.5 billion, with growth portfolio sales up 16% and legacy drugs down 15%. The company expects Eliquis sales to rise despite U.S. price negotiations, but warned of a potential $2 billion drop in 2027 when European patents expire.
5 February 2026
··
Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer stock price edges higher as Wall Street sizes up obesity-shot data and 2026 outlook

Pfizer shares rose 0.8% to $27.01 by early afternoon after the company reported up to 12.3% placebo-adjusted weight loss in a Phase 2b trial of its experimental obesity drug. Investors remain cautious amid concerns over patient dropout rates and side effects. Pfizer reaffirmed its 2026 forecast, projecting $59.5–$62.5 billion in revenue and $2.80–$3.00 adjusted earnings per share.
5 February 2026
···
Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers (HIMS) stock whipsaws on $49 “compounded Wegovy pill” plan as Novo Nordisk threatens legal action

Hims & Hers Health shares surged to $29.44 before falling back to $24.41 after announcing $49 compounded semaglutide pills. Novo Nordisk said it will sue, calling the move illegal mass compounding. The FDA previously warned Hims about misleading claims on compounded semaglutide. Novo’s branded Wegovy pill will cost $199 per month.
5 February 2026
···
Eli Lilly stock slides after $49 Wegovy copy stirs fresh price-war jitters in obesity drugs

Eli Lilly stock slides after $49 Wegovy copy stirs fresh price-war jitters in obesity drugs

Eli Lilly shares fell 6.2% to $1,038.52 Thursday morning after Hims & Hers Health announced a $49-per-month compounded Wegovy pill, undercutting branded obesity drugs. Novo Nordisk shares also dropped 6.8%. Investors focused on Lilly’s ability to protect margins as cheaper alternatives and new pricing models intensify competition. CFO Lucas Montarce warned price cuts will slow growth despite strong demand.
5 February 2026
··
Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop

Pfizer stock jumps nearly 4% — what’s driving PFE after the obesity-drug data drop

Pfizer shares rose 3.9% to $26.78 before holding steady after hours, following new data on its obesity drug PF-3944 and quarterly results. The company maintained its 2026 revenue and earnings outlook but warned of pricing pressures and upcoming patent expirations. Mid-stage trial data showed up to 12.3% weight loss at 28 weeks, with some patients dropping out due to side effects. Trading volume topped 80 million shares.
5 February 2026
·
Merck stock rises after-hours as cautious 2026 forecast meets new cholesterol pill headlines

Merck stock rises after-hours as cautious 2026 forecast meets new cholesterol pill headlines

Merck shares rose 2.2% to $118.33 in after-hours trading Wednesday after new data showed its experimental cholesterol drug enlicitide cut LDL by up to 60% in a major trial. The company’s 2026 revenue forecast of $65.5–$67.0 billion missed Wall Street estimates, citing pressure from off-patent drugs and U.S. pricing. Keytruda sales reached $8.37 billion last quarter, while Gardasil revenue fell 34%.
5 February 2026
···
1 … 3 4 5 6 7 … 38

Stock Market Today

  • Union Pacific Stock Seen Undervalued Amid Recent Price Drop
    March 20, 2026, 2:10 PM EDT. Union Pacific (ticker: UNP) shares dropped roughly 11% over the past month, now trading near $234. Despite this short-term weakness, the railroad operator maintains positive returns of 1% year-to-date and over 20% across five years. A discounted cash flow (DCF) analysis estimates an intrinsic value around $313 per share, indicating the stock trades about 25% below its cash flow-based valuation, suggesting undervaluation. The price-to-earnings (P/E) metric offers another lens but is secondary to DCF in this review. Investors should weigh recent volatility against Union Pacific's strong long-term fundamentals and sector dynamics before deciding whether current weakness presents a buying opportunity.
Go toTop